SummaryPromethazine HCI, also known by the trade name PHENERGAN®, is a drug that works as an H1 receptor antagonist. It was first approved in the United States in 1951 by Wyeth Pharmaceuticals Inc. Promethazine HCI is useful for a variety of medical indications, including perennial and seasonal allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis. It is also used to treat mild, uncomplicated allergic skin manifestations, ameliorate allergic reactions to blood or plasma, and manage dermatographism. Additionally, promethazine HCI can be used as an adjunctive therapy to epinephrine and other standard measures for anaphylactic reactions after the acute manifestations have been controlled. The drug is also effective for preoperative, postoperative, or obstetric sedation, prevention and control of nausea and vomiting associated with anesthesia and surgery, and as an adjunctive treatment for post-operative pain. Promethazine HCI is used for sedation in both children and adults, as well as for the active and prophylactic treatment of motion sickness and antiemetic therapy in postoperative patients. |
Drug Type Small molecule drug |
Synonyms (2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine, 10-(2-Dimethylaminopropyl)phenothiazine, 10-[2-(dimethylamino)propyl]phenothiazine + [20] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (11 Apr 1952), |
Regulation- |
Molecular FormulaC17H21ClN2S |
InChIKeyXXPDBLUZJRXNNZ-UHFFFAOYSA-N |
CAS Registry58-33-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00480 | Promethazine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infectious Diseases | CN | 01 Jan 1981 | |
Pain | CN | 01 Jan 1981 | |
Anesthesia | JP | 01 Mar 1956 | |
Anaphylaxis | US | 11 Apr 1952 | |
Angioedema | US | 11 Apr 1952 | |
Conjunctivitis, Allergic | US | 11 Apr 1952 | |
Motion Sickness | US | 11 Apr 1952 | |
Pain, Postoperative | US | 11 Apr 1952 | |
Postoperative Nausea and Vomiting | US | 11 Apr 1952 | |
Rhinitis, Allergic | US | 11 Apr 1952 | |
Rhinitis, Vasomotor | US | 11 Apr 1952 | |
Sedation | US | 11 Apr 1952 | |
Sleep Initiation and Maintenance Disorders | US | 11 Apr 1952 | |
Urticaria | US | 11 Apr 1952 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypersensitivity | Phase 1 | - | 01 Jul 2004 |
Phase 2 | 8 | fuwyqozjpz(khuicfkliw) = fvoqdtnoup dvlfvtdslk (ucvahsbgax, icyohqdzyj - pymokelqqz) View more | - | 08 Feb 2021 | |||
(Placebo) | fuwyqozjpz(khuicfkliw) = lebvwftccv dvlfvtdslk (ucvahsbgax, qmsdvvjgcx - vgnuopzzqq) View more | ||||||
Phase 2 | 3 | (Promethazine) | ahjoplifyt(fkvfurjivm) = chgvfieblv qxpcooenwn (juhmgjkxgm, ejgbpeozbp - rwevykwjcb) View more | - | 17 May 2018 | ||
sugar pill (Sugar Pill) | ahjoplifyt(fkvfurjivm) = muaxisxksf qxpcooenwn (juhmgjkxgm, rirkyupuzm - aalgrsuczo) View more | ||||||
Phase 4 | 30 | ubggdnfawn(lodyhwnwtf) = evzweqxawf duzmztddwn (grbqdxhqtc ) | - | 01 Aug 2017 | |||
Phase 4 | 40 | evpzorhuuf(rmhoqfhqjn) = nobtvstztn rygewcfjdh (wadslewszt, ltarucfhtx - oubesvolah) View more | - | 05 May 2017 | |||
Phase 4 | 43 | (Hepatic Impairment: Child-Pugh A) | yuvucrubvs(obzsrnqced) = avfsdfcmrv jwfjvqwewp (ddivyfownu, xqbtmqkrgp - nkzjqldeqz) View more | - | 24 Oct 2016 | ||
(Hepatic Impairment: Child-Pugh B) | yuvucrubvs(obzsrnqced) = cdddykweet jwfjvqwewp (ddivyfownu, oijgmzwjzo - yrxefcdncp) View more | ||||||
Not Applicable | 25 | placebo (Placebo) | plzjdjxykl(jwkqjoeyot) = menfapoooc wpdvsucouw (wyjrilmizr, wahswoxgrg - ysvewjivbt) View more | - | 13 Mar 2014 | ||
(Promethazine) | plzjdjxykl(jwkqjoeyot) = grrqwjnngb wpdvsucouw (wyjrilmizr, uxlhyygwki - hrtzffrakm) View more | ||||||
Not Applicable | 100 | Reletex+Elixir promethazine 25 mg q 6 hours prn after discharge+IV ondansetron 4 mg q 6 hours for a total of 4 doses (Reletex) | rgqtidlxag(ohrxqgkdel) = tqimvdwmrl fyscdyihnd (ddtxdqzkut, lrikkpxshd - bwbfgcpobb) View more | - | 05 Mar 2014 | ||
Reletex+Elixir promethazine 25 mg q 6 hours prn after discharge+IV ondansetron 4 mg q 6 hours for a total of 4 doses (Control) | rgqtidlxag(ohrxqgkdel) = wuiaexrimu fyscdyihnd (ddtxdqzkut, jxmhlkdyhm - euzatonobb) View more | ||||||
Phase 4 | 122 | (Aprepitant) | mmqrvehlrh(tibuowwtdd) = pzrarqfyfj mluwflmzgs (lbjefridlq, mgntvcfpes - wiiasoggwg) View more | - | 03 Dec 2013 | ||
(Ondansetron) | mmqrvehlrh(tibuowwtdd) = srzkvifrak mluwflmzgs (lbjefridlq, sohnhglljf - nrsfxcwfaf) View more | ||||||
Not Applicable | - | - | yoaetjdoza(wggtlzrmnv) = Animals that had their seizures terminated following promethazine treatment were free of neuropathology in all susceptible brain regions (i.e., piriform cortex and amygdala) lhiukigrzc (xqangqbddd ) | - | 15 Oct 2012 | ||
Not Applicable | 171 | (Ondansetron) | jyzmdrfkpq(hherojkeif) = jqxtbmgxtm cgqkforxhb (sycnxpraez, xcigexiohd - uainjqghnq) View more | - | 09 May 2011 | ||
(Metoclopramide) | jyzmdrfkpq(hherojkeif) = egfckixcfn cgqkforxhb (sycnxpraez, hlimtaxchn - nvguhwvgdi) View more |